186393-22-6

Basic information

• Product Name: (3R,4S)-tert-butyl 3,4-dihydroxypyrrolidine-1-carboxylate
• Synonyms: (3R,4S)-tert-butyl 3,4-dihydroxypyrrolidine-1-carboxylate;rel-(3R,4S)-tert-Butyl 3,4-dihydroxypyrrolidine-1-carboxylate;cis-tert-butyl 3,4-dihydroxypyrrolidine-1-carboxylate;tert-Butyl (3R,4S)-3,4-dihydroxypyrrolidine-1-carboxylate;tert-butyl-cis-3,4-dihydroxypyrrolidine-1-carboxylate;1-Pyrrolidinecarboxylic acid, 3,4-dihydroxy-, 1,1-dimethylethyl ester, (3R,4S)-rel-
• CAS NO: 186393-22-6
• Molecular Formula: C9H17NO4
• Molecular Weight: 203.23558
• Mol File: 186393-22-6.mol

Chemical Properties

• Boiling Point: 300.6±42.0 °C(Predicted)
• Appearance: /
• Density: 1.262±0.06 g/cm3(Predicted)
• PKA: 13.91±0.40(Predicted)
• CAS DataBase Reference: (3R,4S)-tert-butyl 3,4-dihydroxypyrrolidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (3R,4S)-tert-butyl 3,4-dihydroxypyrrolidine-1-carboxylate(186393-22-6)
• EPA Substance Registry System: (3R,4S)-tert-butyl 3,4-dihydroxypyrrolidine-1-carboxylate(186393-22-6)

Safety Data

• Hazardous Substances Data: 186393-22-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(3R,4S)-tert-butyl 3,4-dihydroxypyrrolidine-1-carboxylate is used as a pharmaceutical intermediate for the synthesis of various drugs. Its unique structure and functional groups make it a valuable building block in the development of new pharmaceutical compounds, contributing to the advancement of drug discovery and innovation.
Used in Chemical Synthesis:
(3R,4S)-tert-butyl 3,4-dihydroxypyrrolidine-1-carboxylate is also used as a key intermediate in the synthesis of various chemical compounds. Its reactivity and structural features allow for the creation of a wide range of products, making it a valuable asset in the field of chemical synthesis and research.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 90365-74-5 (3S,4S)-(+)-1-benzyl-3,4-pyrrolidinediol 
• 73286-70-1 N-(tert-butoxycarbonyl)-3-pyrroline 
• 114214-49-2 rac-tert-butyl (1R,5S)-6-oxa-3-azabicyclo[3.1.0]hexane-3-carboxylate 
• 86953-79-9 tert-butyl pyrrolidine-1-carboxylate 
• 114214-49-2 1-tert-butoxycarbonyl-3,4-epoxypyrrolidine 
• 4248-19-5 tert-butyl carbazate 
• 151259-38-0 tert-butyl diallylcarbamate 
• 60138-51-4 tert-butyl 2,5-dihydropyrrole 
• 163439-82-5 (3R,4R)-1-benzyl-3,4-pyrrolidinediol 
• 186393-31-7 (3R,4R)-pyrrolidine-3,4-diol 
• 1428671-12-8 (3S,4S)-1-(tert-butoxycarbonyl)-3,4-pyrrolidinediyl diacetate 
• 762-75-4 tert-butyl formate 
• 90481-32-6 (3S,4S)-pyrrolidine-3,4-diol 

Downstream Products

• 945217-60-7 tert-butyl (3R,4S)-3,4-diaminopyrrolidine-1-carboxylate 
• 694439-03-7 tert-butyl (4aR,7aS)-hexahydro-2H-[1,4]dioxino[2,3-c]pyrrole-6-carboxylate 
• 148214-86-2 rac-tert-butyl (3R,4S)-3-hydroxy-4-methoxypyrrolidine-1-carboxylate 
• 56074-20-5 N-((tert-butyloxy)carbonyl)iminodiacetic acid 
• 148214-86-2 tert-butyl (3R,4R)-3-hydroxy-4-methoxypyrrolidine-1-carboxylate 
• 694439-03-7 tert-butyl (4aS,7aS)-hexahydro-6H-[1,4]dioxino[2,3-c]pyrrolidine-6-carboxylate 
• 372482-11-6 tert-butyl (3S,4S)-3-hydroxy-4-methoxypyrrolidine-1-carboxylate 
• 276862-76-1 (3S,4S)-pyrrolidine-3,4-diol hydrochloride 

Relevant articles and documents

Discovery of 1-pyrimidinyl-2-aryl-4,6-dihydropyrrolo [3,4-d]imidazole-5(1H)-carboxamide as a novel JNK inhibitor

We designed and synthesized 1-pyrimidinyl-2-aryl-4, 6-dihydropyrrolo [3,4-d] imidazole-5(1H)-carboxamide derivatives as selective inhibitors of c-Jun-N-terminal Kinase 3 (JNK3), a target for the treatment of neurodegenerative diseases. Based on the compounds found in previous studies, a novel scaffold was designed to improve pharmacokinetic characters and activity, and compound 18a, (R)-1-(2-((1-(cyclopropanecarbonyl)pyrrolidin-3-yl)amino)pyrimidin-4-yl)-2-(3,4-dichlorophenyl)-4,6-dihydro pyrrolo [3,4-d]imidazole-5(1H)-carboxamide, showed the highest IC50 value of 2.69 nM. Kinase profiling results also showed high selectivity for JNK3 among 38 kinases, having mild activity against JNK2, RIPK3, and GSK3β, which also known to involve in neuronal apoptosis.

Selective Isomerization via Transient Thermodynamic Control: Dynamic Epimerization of trans to cis Diols

Traditional approaches to stereoselective synthesis require high levels of enantio- and diastereocontrol in every step that forms a new stereocenter. Here, we report an alternative approach, in which the stereochemistry of organic substrates is selectivel

COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES

The present invention provides a compound of formula (Ia) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, solid forms, combinations of pharmacologically active agents, pharmaceutical compositions and methods of using such compounds and solid forms thereof to treat or prevent parasitic diseases, for example malaria.

Compound JK-03M having higher protein kinase G inhibitory activity or pharmaceutically acceptable salt thereof and preparation method thereof

The invention discloses a compound which has higher protein kinase G inhibitory activity and is shown in a formula I or pharmaceutically acceptable salt thereof and a preparation method thereof. The compound JK-03M having the higher protein kinase G inhibitory activity comprises a pharmaceutical composition of a new compound and application of the new compound in treatment of pain, in particular to chronic pain. The formula (1) is shown in the description.

SUBSTITUTED TRICYCLICS AND METHOD OF USE

The present invention provides for compounds of formula (I) wherein X, Y, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sj?gren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1

The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): (Iar) wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

1 -OXO-1,2-DIHYDROISOQUINOLIN-7-YL-(5-SUBSTITUTED-THIOPHEN-2-YL)-SULFONAMIDE COMPOUNDS, FORMULATIONS CONTAINING THOSE COMPOUNDS, AND THEIR USE AS AICARFT INHIBITORS IN THE TREATMENT OF CANCERS

1-Oxo-1,2-dihydroisoquinolin-7-yl-(5-substituted-thiophen-2-yl)-sulfonamide compounds, formulations containing those compounds, and their use as AICARFT inhibitors.

Compounds with higher PKG (protein kinase G) inhibitory activity and preparation method of compounds

The invention discloses compounds which have higher PKG (protein kinase G) inhibitory activity and are represented as a formula I, pharmaceutically acceptable salts, pharmaceutical composition containing the novel compounds, as well as an application of the novel compounds in treatment of pain, especially chronic pain. The invention further discloses a preparation method of the compounds and new intermediates. R1 and R2 are the same or different and are selected from a group comprising halogen (such as F or Cl), C1-C6 alkoxy, C1-C6 alkyl, C2-C6 alkenyl and C2-C6 alkynyl; R3 is a terminal group and is selected from a group comprising H, halogen, alkyl, naphthenic base, alkenyl, alkynyl, aryl and heteroaryl; n is the number of repetitive units and is an integer in a range from 1 to 15.

COMPOUND HAVING HIGHER INHIBITION OF PROTEIN KINASE G ACTIVITY AND PREPARATION METHOD THEREFOR

Disclosed are a compound of Formula I having higher inhibition of protein kinase G (PKG) activity and pharmaceutically acceptable salts thereof. In Formula I, R1 and R2 are the same or different, each being independently chosen from the halogens, the C1-C6 alkoxyl group, the C1-C6 alkyl group, the C2-C6 alkenyl group, and the C2-C6 alkynyl group; R3 is chosen from H, the halogens, the substituted or unsubstituted C1-C6 alkyl group, C3-C6 cycloalkyl group, C2-C6 alkenyl group, and C2-C6 alkynyl group, aryl group, and heteroaryl group; and n is an integer between 0 and 15. Also disclosed is a pharmaceutical composition comprising said compound, the use of the compound in treating pains, in particular chronic pain, a preparation method for the compound, and a new intermediate.

AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS

Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.